Combination cancer immunotherapies with arginine depletion agents
US12281339B2 · kind B2 · utility
0Cited by
12References
32Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 5, 2017 |
| Grant date | Apr 22, 2025 |
| Priority date | — |
| Expiry date | Jul 5, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y305/03006
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are arginine depletion agents such as ADI-PEG for use in combination with cancer immunotherapies, for example, immune checkpoint modulators and T-cell adoptive immunotherapies, for treating various cancers. Also provided are related methods, compositions, patient care kits, and cell cultures.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.